medigraphic.com
ISSN 0188-2198 (Print)

2015, Number 2

<< Back Next >>

Rev Mex Cardiol 2015; 26 (2)

Beneficial effects of a flavanol-enriched cacao beverage on anthropometric and cardiometabolic risk profile in overweight subjects

Munguía L, Gutiérrez-Salmeán G, Hernández M, Ortiz A, Sánchez ME, Nájera N, Meaney E, Rubio-Gayosso I, Ceballos G

Language: English
References: 27
Page: 78-86
PDF size: 247.02 Kb.


ABSTRACT

Overweight and obesity are associated with systemic inflammation and oxidative stress which, in turn, enhance the development of cardiometabolic disruptions. Lifestyle changes and pharmacologic approaches show moderately effective results regarding overall health improvements. Evidence suggests that cacao flavonoids are associated with a reduced cardiometabolic risk, due to the modulation of molecular pathways subjacent to glucose and lipids metabolism. The aim of this study was to assess the effects of cacao flavonoids supplementation on anthropometric and cardiometabolic risk factors in overweight subjects. A double-blind, placebo-controlled, pilot clinical trial was conducted in overweight subjects with borderline criteria of metabolic syndrome. Participants were randomly assigned to either, supplement of cacao flavonoids (80 mg) or placebo, daily, for 4 weeks. Cardiometabolic variables were blood pressure, glycemia and lipid profile. Serum markers of oxidative damage (free protein carbonyls and malondialdehyde) were also analyzed. Anthropometric measurements included body weight, body mass index, waist circumference, and fat and fat-free mass. We found significant reductions in body weight (p = 0.04), waist circumference (p = 0.03), triacylglycerols (p ‹ 0.01), TG/HDL ratio (p = 0.01), MDA (p = 0.02) and protein carbonyls (p = 0.01) in the flavonoid-supplemented group. Results from this study show that cacao flavonoids can effectively modulate anthropometric and cardiometabolic risk factors.


REFERENCES

  1. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr. 2004; 79 (5): 727-747.

  2. Zamora-Ros R, Forouhi NG, Sharp SJ, Gonzalez CA, Buijsse B, Guevara M, et al. Dietary intakes of individual flavanols and flavonols are inversely associated with incident type 2 diabetes in European populations. J Nutr. 2014; 144 (3): 335-343. Epub 2013/12/26.

  3. Bastard JP, Maachi M, Lagathu C, Kim MJ, Caron M, Vidal H, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Network. 2006; 17 (1): 4-12.

  4. Visioli F, Bernaert H, Corti R, Ferri C, Heptinstall S, Molinari E, et al. Chocolate, lifestyle, and health. Criti Rev Food Sci Nutr. 2009; 49 (4): 299-312.

  5. Galleano M, Oteiza PI, Fraga CG. Cacao, chocolate, and cardiovascular disease. J Cardiovas Pharmacol. 2009; 54 (6): 483-490.

  6. Beekmann K, Actis-Goretta L, van Bladeren PJ, Dionisi F, Destaillats F, Rietjens IM. A state-of-the-art overview of the effect of metabolic conjugation on the biological activity of flavonoids. Food Funct. 2012; 3 (10): 1008-1018.

  7. Kong AN, Yu R, Chen C, Mandlekar S, Primiano T. Signal transduction events elicited by natural products: role of MAPK and caspase pathways in homeostatic response and induction of apoptosis. Arch Pharmacol Res. 2000; 23 (1): 1-16.

  8. Moreno-Ulloa A, Romero-Perez D, Villarreal F, Ceballos G, Ramirez-Sanchez I. Cell membrane mediated (-)-epicatechin effects on upstream endothelial cell signaling: evidence for a surface receptor. Bioorg Med Chem Letters. 2014; 24 (12): 2749-2752.

  9. Cordero-Herrera I, Martin MA, Goya L, Ramos S. Cacao flavonoids protect hepatic cells function against high glucose-induced oxidative stress. Relevance of MAPKs. Mol Nutr Food Res. 2015; 59 (4): 597-609.

  10. Blumberg JB, Ding EL, Dixon R, Pasinetti GM, Villarreal F. The science of cacao flavanols: bioavailability, emerging evidence, and proposed mechanisms. Adv Nutr. 2014; 5 (5): 547-549.

  11. Dalle-Donne I, Rossi R, Colombo R, Giustarini D, Milzani A. Biomarkers of Oxidative Damage in Human Disease. Clin Chem. 2006; 52 (4): 601-623.

  12. Pirinccioglu AG, Gokalp D, Pirinccioglu M, Kizil G, Kizil M. Malondialdehyde (MDA) and protein carbonyl (PCO) levels as biomarkers of oxidative stress in subjects with familial hypercholesterolemia. Clin Biochem. 2010; 43 (15): 1220-1224.

  13. da Luz PL, Favarato D, Junior JRF-N, Lemos P, Chagas ACP. High ratio of triglycerides to HDL-cholesterol predicts extensive coronary disease. Clinics. 2008; 63 (4): 427-432.

  14. Matsui N, Ito R, Nishimura E, Yoshikawa M, Kato M, Kamei M et al. Ingested cacao can prevent high-fat dietinduced obesity by regulating the expression of genes for fatty acid metabolism. Nutr. 2005; 21 (5): 594-601.

  15. Mursu J, Voutilainen S, Nurmi T, Rissanen TH, Virtanen JK, Kaikkonen J et al. Dark chocolate consumption increases HDL cholesterol concentration and chocolate fatty acids may inhibit lipid peroxidation in healthy humans. Free Rad Biol Med. 2004; 37 (9): 1351-1359.

  16. Lamon-Fava S. Genistein activates apolipoprotein A-I gene expression in the human hepatoma cell line hep G2. J Nutr. 2000; 130 (10): 2489-2492.

  17. Haas MJ, Onstead-Haas LM, Szafran-Swietlik A, Kojanian H, Davis T, Armstrong P et al. Induction of hepatic apolipoprotein A-I gene expression by the isoflavones quercetin and isoquercetrin. Life Sci. 2014; 110 (1): 8-14.

  18. Ikeda I, Hamamoto R, Uzu K, Imaizumi K, Nagao K, Yanagita T et al. Dietary gallate esters of tea catechins reduce deposition of visceral fat, hepatic triacylglycerol, and activities of hepatic enzymes related to fatty acid synthesis in rats. Biosci Biotech Biochem. 2014; 69 (5): 1049-1053.

  19. Murguía-Romero M, Jiménez-Flores JR, Sigrist-Flores SC, Espinoza-Camacho MA, Jiménez-Morales M, Piña E et al. Plasma triglyceride/HDL-cholesterol ratio, insulin resistance, and cardiometabolic risk in young adults. J Lipid Res. 2013; 54 (10): 2795-2799.

  20. Piva SJ, Tatsch E, De Carvalho JAM, Bochi GV, Kober H, Duarte T et al. Assessment of inflammatory and oxidative biomarkers in obesity and their associations with body mass index. Inflammation. 2013; 36 (1): 226-231.

  21. Dansky HM, Charlton SA, Barlow CB, Tamminen M, Smith JD, Frank JS et al. Apo A-I inhibits foam cell formation in Apo E-deficient mice after monocyte adherence to endothelium. J Clin Invest. 1999; 104 (1): 31-39.

  22. Itabe H, Hosoya R, Karasawa K, Jimi S, Saku K, Takebayashi S et al. Metabolism of oxidized phosphatidylcholines formed in oxidized low density lipoprotein by lecithin-cholesterol acyltransferase. J Biochem. 1999; 126 (1): 153-161.

  23. Baynes JW, Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes. 1999; 48 (1): 1-9.

  24. Chen K, Xie F, Liu S, Li G, Chen Y, Shi W et al. Plasma reactive carbonyl species: Potential risk factor for hypertension. Free Rad Res. 2011; 45 (5): 568-574.

  25. Caimi G, Lo Presti R, Montana M, Noto D. Lipid peroxidation, nitric oxide metabolites, and their ratio in a group of subjects with metabolic syndrome. Oxid Med Cell Longev. 2014; 2014: 824756.

  26. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metabol Cardiovasc Dis. 2005; 15 (4): 316-328.

  27. Gusi N, Olivares PR, Rajendram R. The EQ-5D healthrelated quality of life questionnaire. New York, NY: Springer New York; 2010. p. 87-99.




2020     |     www.medigraphic.com